CDX-301: Clinical Trials

7 trials of CDX-301, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 active not recruiting, 3 completed, 1 recruiting. 7 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 17Active not recruiting 3, Completed 3, Recruiting 1
Phase 21Completed 1

Follow CDX-301: new trials by email Literature Review of CDX-301 trials Research Report on CDX-301

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Poly ICLC, Radiation Therapy - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
Phase 1Active not recruitingUniversity of Southern California142023-01-092026-06-18
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
PLD Chemotherapy, CDX-1140, CDX-301 - HER2-negative Breast Cancer, Metastatic Breast Cancer
Phase 1RecruitingUniversity of Texas Southwestern Medical Center302022-04-202026-06-17
The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.
PGV-001, Poly-ICLC, CDX-301 - Prostate Cancer
Phase 1Active not recruitingAshutosh Kumar Tewari272022-01-052026-01-07
NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma
CDX-301, NEOVAX, Nivolumab - Melanoma, Metastatic Melanoma
Phase 1Active not recruitingDana-Farber Cancer Institute102022-01-032026-03-25
Vaccination With Flt3L, Radiation, and Poly-ICLC
Pembrolizumab, Flt3L, Radiation - Non-Hodgkin's Lymphoma, Metastatic Breast Cancer
Phase 1 / Phase 2CompletedIcahn School of Medicine at Mount Sinai172019-04-052026-05-22
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
CDX-1140, CDX-301, pembrolizumab - Melanoma, Non-small Cell Lung Cancer
Phase 1CompletedCelldex Therapeutics1322017-12-012024-03-28
A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers
CDX-301 - Healthy
Phase 1CompletedCelldex Therapeutics302011-10-012017-06-27

Conditions studied

Breast Neoplasms (4)  ·  Melanoma (3)  ·  Lymphoma, Non-Hodgkin (2)  ·  Bile Duct Neoplasms (1)  ·  Bone Neoplasms (1)  ·  Carcinoma (1)  ·  Carcinoma, Basal Cell (1)  ·  Carcinoma, Merkel Cell (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Renal Cell (1)  ·  Cholangiocarcinoma (1)  ·  Colorectal Neoplasms (1)  ·  Esophageal Neoplasms (1)  ·  Fallopian Tube Neoplasms (1)  ·  Gastrointestinal Neoplasms (1)

Sponsors

Celldex Therapeutics (2)  ·  Ashutosh Kumar Tewari (1)  ·  Dana-Farber Cancer Institute (1)  ·  Icahn School of Medicine at Mount Sinai (1)  ·  University of Southern California (1)  ·  University of Texas Southwestern Medical Center (1)

Countries

United States (7)

Top investigators

Ashutosh Tewari, MD (1)  ·  Dara Lundon, MD MSc MBA PhD (1)  ·  Fumito Ito, MD (1)  ·  Joshua Brody, MD (1)  ·  Patrick A Ott, MD, PhD (1)  ·  Sangeetha Reddy (1)  ·  Sujit S Nair, Ph.D. (1)

NIH funding

K08CA267189 (1)